Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2020-11-25 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin launches Tacrolimus Capsules USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Tacrolimus Capsules USP by Lupin Limited following FDA approval of an ANDA by its alliance partner. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 4261 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory filings. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-11-25 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Tacrolimus Capsules USP by Lupin Limited following FDA approval of an ANDA by its alliance partner. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 4261 characters, which is relatively short and typical for a press release. There is no financial data, no meeting materials, no voting results, no audit or legal information, no capital or share issuance details, and no executive changes. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2020-11-25 English
Transcript of Q2 FY2021 Earnings Conference Call on Thursday, November 5, 2020.
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q2 FY2021 earnings conference call for Lupin Limited, dated November 5, 2020. It includes management commentary on quarterly financial results, revenue growth, segment performance, cost analysis, and outlook. The text contains a Q&A session with analysts discussing financial and operational details. The presence of detailed financial figures, management discussion, and Q&A about quarterly performance clearly identifies this as a Call Transcript (CT) of an earnings conference call. The document is lengthy (15,000 characters) and contains the full transcript, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA). Therefore, the correct classification is Call Transcript (CT).
2020-11-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of the Q2 FY2021 earnings conference call for Lupin Limited, dated November 5, 2020. It includes detailed discussions of quarterly financial results, revenue growth, EBITDA, segment performance, and outlook. The text contains a Q&A session with analysts, which is typical of earnings call transcripts. The document references specific quarterly financial data and management commentary on performance and future expectations. It is not an announcement or a brief summary but a full transcript of the earnings call. Therefore, the appropriate classification is Call Transcript (CT).
2020-11-24 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to related party transactions and balances for the half year ended September 30, 2020. It contains detailed financial data on transactions and balances with related parties, including key management personnel and entities with significant influence. The document is not a full interim or annual report but a regulatory disclosure specific to related party transactions. It is not an announcement of a report but the actual disclosure itself with substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-11-12 English
Consolidated disclosure of Related Party Transactions and balances for the half year ended September 30, 2020.
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to related party transactions and balances for the half year ended September 30, 2020. It contains detailed financial data on transactions and balances with related parties, including key management personnel and entities with significant influence. The document is not a full financial report like an Annual Report or Interim Report but a specific regulatory disclosure about related party transactions. It is not an announcement or a certification but contains substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance disclosures that do not fit other specific categories.
2020-11-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.